Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC10914 in mCRPC with BRCA Mutation
CTR20200047Phase 2Active
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SC10914 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Started Jun 2020; status: active.
02
Drugs
SC10914
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20200047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200047.